Mereo BioPharma Group Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Mereo BioPharma Group has been growing earnings at an average annual rate of 29.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 4.6% per year.
Anahtar bilgiler
29.1%
Kazanç büyüme oranı
59.8%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 4.6% |
Özkaynak getirisi | -46.8% |
Net Marj | -3,684.7% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Gelir ve Gider Dağılımı
Mereo BioPharma Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 1 | -37 | 23 | 16 |
31 Mar 24 | 10 | -26 | 18 | 15 |
31 Dec 23 | 10 | -29 | 18 | 16 |
30 Sep 23 | 10 | -32 | 21 | 18 |
30 Jun 23 | 9 | -32 | 24 | 19 |
31 Mar 23 | 0 | -42 | 27 | 24 |
31 Dec 22 | 0 | -42 | 26 | 28 |
30 Sep 22 | 0 | -31 | 22 | 29 |
30 Jun 22 | 0 | -23 | 20 | 33 |
31 Mar 22 | 24 | -4 | 21 | 33 |
31 Dec 21 | 49 | 17 | 22 | 32 |
30 Sep 21 | 49 | -10 | 25 | 28 |
30 Jun 21 | 50 | -37 | 30 | 25 |
31 Mar 21 | 25 | -131 | 30 | 23 |
31 Dec 20 | 0 | -224 | 29 | 22 |
30 Sep 20 | 0 | -198 | 25 | 24 |
30 Jun 20 | 0 | -177 | 21 | 25 |
31 Mar 20 | 0 | -111 | 20 | 27 |
31 Dec 19 | 0 | -46 | 21 | 31 |
30 Sep 19 | 0 | -41 | 18 | 29 |
30 Jun 19 | 0 | -40 | 18 | 30 |
31 Mar 19 | 0 | -41 | 17 | 30 |
31 Dec 18 | 0 | -41 | 15 | 29 |
30 Sep 18 | 0 | -42 | 15 | 30 |
30 Jun 18 | 0 | -44 | 14 | 32 |
31 Mar 18 | 0 | -50 | 15 | 41 |
31 Dec 17 | 0 | -52 | 14 | 47 |
30 Sep 17 | 0 | -50 | 14 | 47 |
30 Jun 17 | 0 | -47 | 12 | 45 |
31 Mar 17 | 0 | -41 | 13 | 37 |
31 Dec 16 | 0 | -35 | 14 | 30 |
30 Jun 16 | 0 | -39 | 22 | 23 |
Kaliteli Kazançlar: MREO is currently unprofitable.
Büyüyen Kar Marjı: MREO is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MREO is unprofitable, but has reduced losses over the past 5 years at a rate of 29.1% per year.
Büyüme Hızlandırma: Unable to compare MREO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: MREO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: MREO has a negative Return on Equity (-46.85%), as it is currently unprofitable.